HC Wainwright Has Bearish Forecast for HRMY Q3 Earnings

Key Points

• HC Wainwright has revised its Q3 2025 earnings estimate for Harmony Biosciences down to $0.83 per share, from a previous forecast of $0.99.
• Harmony Biosciences recently reported a quarterly EPS of $0.68, which was below analysts' expectations of $0.78.
• Despite a decrease in EPS estimates, the company maintains a consensus rating of "Buy" among research analysts, with a target price of $51.00.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - HC Wainwright reduced their Q3 2025 earnings estimates for Harmony Biosciences in a research report issued to clients and investors on Wednesday, August 6th. HC Wainwright analyst P. Trucchio now expects that the company will earn $0.83 per share for the quarter, down from their previous forecast of $0.99. The consensus estimate for Harmony Biosciences' current full-year earnings is $2.43 per share. HC Wainwright also issued estimates for Harmony Biosciences' Q4 2025 earnings at $1.28 EPS.

HRMY has been the topic of several other research reports. Cantor Fitzgerald upgraded shares of Harmony Biosciences to a "strong-buy" rating in a research note on Tuesday, May 13th. UBS Group lowered their price objective on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Monday, April 28th. The Goldman Sachs Group began coverage on shares of Harmony Biosciences in a research note on Thursday, July 10th. They set a "neutral" rating and a $33.00 price objective on the stock. Wall Street Zen lowered shares of Harmony Biosciences from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, Needham & Company LLC reiterated a "buy" rating and set a $49.00 price objective on shares of Harmony Biosciences in a research note on Tuesday, May 6th. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $51.00.

Harmony Biosciences Stock Performance

Shares of NASDAQ:HRMY remained flat at $34.19 during trading hours on Friday. 413,410 shares of the company's stock traded hands, compared to its average volume of 625,689. The firm has a fifty day moving average price of $34.16 and a two-hundred day moving average price of $33.80. Harmony Biosciences has a 12 month low of $26.47 and a 12 month high of $41.61. The firm has a market capitalization of $1.97 billion, a price-to-earnings ratio of 11.03, a price-to-earnings-growth ratio of 0.42 and a beta of 0.84. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.84 and a quick ratio of 3.63.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $0.68 EPS for the quarter, missing the consensus estimate of $0.78 by ($0.10). Harmony Biosciences had a net margin of 23.44% and a return on equity of 26.34%. The firm had revenue of $200.49 million during the quarter, compared to analyst estimates of $204.37 million. During the same quarter in the previous year, the business posted $1.05 EPS. Harmony Biosciences's revenue for the quarter was up 16.0% compared to the same quarter last year.

Institutional Trading of Harmony Biosciences

Large investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC boosted its holdings in Harmony Biosciences by 222.9% during the first quarter. GAMMA Investing LLC now owns 2,929 shares of the company's stock worth $97,000 after buying an additional 2,022 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Harmony Biosciences by 52.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 20,221 shares of the company's stock worth $671,000 after buying an additional 6,915 shares in the last quarter. Arizona State Retirement System boosted its holdings in Harmony Biosciences by 6.4% during the first quarter. Arizona State Retirement System now owns 12,261 shares of the company's stock worth $407,000 after buying an additional 737 shares in the last quarter. Two Sigma Advisers LP boosted its holdings in Harmony Biosciences by 21.8% during the fourth quarter. Two Sigma Advisers LP now owns 98,900 shares of the company's stock worth $3,403,000 after buying an additional 17,700 shares in the last quarter. Finally, SG Americas Securities LLC boosted its holdings in Harmony Biosciences by 56.0% during the first quarter. SG Americas Securities LLC now owns 35,097 shares of the company's stock worth $1,165,000 after buying an additional 12,599 shares in the last quarter. 86.23% of the stock is currently owned by institutional investors.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.